Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Revenue (2016 - 2026)

Anika Therapeutics has reported Revenue over the past 17 years, most recently at $29.6 million for Q1 2026.

  • Quarterly Revenue rose 13.16% to $29.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $116.3 million through Mar 2026, down 0.67% year-over-year, with the annual reading at $112.8 million for FY2025, 5.91% down from the prior year.
  • Revenue was $29.6 million for Q1 2026 at Anika Therapeutics, down from $30.6 million in the prior quarter.
  • Over five years, Revenue peaked at $44.3 million in Q2 2023 and troughed at -$2.9 million in Q4 2023.
  • The 5-year median for Revenue is $30.6 million (2024), against an average of $29.2 million.
  • Year-over-year, Revenue plummeted 107.78% in 2022 and then soared 1155.61% in 2024.
  • A 5-year view of Revenue shows it stood at -$2.8 million in 2022, then dropped by 4.02% to -$2.9 million in 2023, then soared by 1155.61% to $30.6 million in 2024, then grew by 0.04% to $30.6 million in 2025, then fell by 3.28% to $29.6 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Revenue are $29.6 million (Q1 2026), $30.6 million (Q4 2025), and $27.8 million (Q3 2025).